Focusing on accelerating the development of new productivity and promoting the high-quality development of the biomedical industry, on March 25, Zhu Zhisong, member of the Standing Committee of the Municipal Party Committee and Secretary of the District Party Committee, successively visited five enterprises and scientific research institutions engaged in the biomedical industry.
On the morning of the same day, the district leaders came to Hansoh Pharmaceutical Group Co., Ltd. and Shanghai Kezhou Pharmaceutical R&D Co., Ltd. to conduct field research, discuss and exchange with the person in charge of the enterprise, and promote the local industrialization of the original innovative drugs. As a national high-tech enterprise and a national technological innovation demonstration enterprise, Hansoh Pharmaceutical's innovation capabilities rank among the best among domestic pharmaceutical companies, focusing on key therapeutic areas such as anti-tumor, anti-infection, central nervous system diseases, metabolic diseases and autoimmune diseases.
Kezhou Pharmaceutical is also a new drug research and development company focusing on scientific innovation, which is currently in a period of rapid growth and gradual harvest. The company's self-developed melanoma indication for NRAS gene mutations has just received new drug approval this month and officially entered the full commercialization stage, which is the company's first successful transformation of innovation.
Zhu Zhisong pointed out that the biomedical industry is one of the three leading industries entrusted by the CPC Central Committee to Shanghai's mission and priority development, as the "main front" of Shanghai's development of the biomedical industry, Pudong New Area will shoulder the "great power of the country", focusing on four aspects of work, including supporting basic biomedical research, supporting the transformation of clinical research results, accelerating the approval and review of drugs and medical devices, strengthening the construction of biomedical production bases, and providing the whole process and full life cycle services for the local industrialization of original innovative drugs and medical devices. It is expected that the company will realize the transformation and implementation of achievements in Pudong, improve the accessibility of innovative products, and benefit more patients faster and more extensively.
In the afternoon, the district leaders first came to Shanghai Baiying Biotechnology Co., Ltd. and AIMSEN Biomedical (Shanghai) Co., Ltd. in Zhoupu Town to conduct research. Baiying Biotech is a CRO company with the mission of "accelerator of antibody discovery", with a number of core technology platforms such as high-throughput antibody expression platform, antibody discovery and optimization platform, and stable cell line construction platform, serving nearly 1,500 innovative macromolecule drug R&D enterprises and scientific research institutions in more than 20 countries and regions. The core team of Amson Biomedical focuses on the early incubation of the field of enzymatic DNA synthesis, and has completed the feasibility study of related technologies, and is expected to release the latest results in the near future, bringing industrial upgrading in the field of total synthesis and all-round upgrading of existing commercial synthesis.
Zhu Zhisong had a detailed understanding of the development history, core technology and short-term and long-term planning of the two companies, inspected the experimental equipment and the latest products, and had in-depth communication with the heads of the two companies. He said that the biomedical industry chain is very long and there are many innovation points, and it is great to see that so many young people are willing to base themselves in Pudong and take root in the industry to carry out innovative research and development work. There are nearly 4,000 enterprises in the biomedical field in Pudong, and we will further build a platform and create a stage to provide support for the needs of enterprises and the expectations of scientific researchers, promote exchanges and cooperation between enterprises in the industrial chain, so that innovative start-ups and teams can focus on scientific research without worries and achieve better development in Pudong.
On the same day, the district leaders also visited and investigated the System Biosynthesis Research Center of China Pharmaceutical Industry Research Institute. Founded in 2021, the System Biosynthesis Research Center is committed to becoming a leading integrated platform for the intelligent manufacturing of synthetic biological drugs in China, providing new technologies and new varieties for the high-quality development of pharmaceutical enterprises.
Zhu Zhisong said that the General Institute of Medical Industry is an important support for Pudong to promote the development of the biomedical industry, especially the development of the new track of synthetic biology, and Pudong will fully support the General Institute of Medical Industry to become bigger and stronger in Pudong, and work together to open a new chapter in the cooperation between the government and the hospital. The two sides should focus on the needs of national strategic development and the needs of people's lives, health and safety, strengthen communication and linkage, give full play to functional advantages, achieve leadership, empower the development of upstream and downstream small and medium-sized enterprises in the industry, and open up the innovation chain and value chain for key national industries.
Wu Qiang, member of the Standing Committee of the District Party Committee and deputy head of the district, participated in the relevant investigation.
Character: Wang Yan
Photo: Huang Riyue
Editor: Wang Yumeng
* Please indicate that the reprint is from the official WeChat of Pudong